Objectives: To summarise the current body of published evidence on the use of low-dose and/or adjuvant methadone in the palliative care setting.
Methods: The authors searched multiple databases (PubMED, SCORPUS, EMBASE and the Cochrane library) for relevant articles using the terms 'methadone', 'palliative', 'low dose' and 'adjuvant'. The review was restricted to articles published between 2003 and 2018. Paediatric and single-case studies were also excluded. Evidence quality was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) method.
Results: Our search yielded 171 results, of which seven met the inclusion criteria. Four were retrospective chart reviews, one was a retrospective cohort study, one was a case series and one was a double-blind randomised control trial. The overall quality was found to be very low. Of the seven articles, all seven reported some improvement in pain with the addition of low-dose or adjuvant methadone. This improvement was statistically significant in four out of seven articles; statistical significance was not commented on in the remaining three articles.
Conclusion: While case series and chart reviews offer promising results about the utility of adjuvant and/or low-dose methadone in the management of complex pain, the very low evidence quality, relative dearth of studies and near absence of randomised controlled trials make it impossible to draw firm conclusions. Thus, while very preliminary evidence suggests methadone is a potentially effective and valuable agent, further research must be performed before such findings can be implemented into clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bmjspcare-2018-001695 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The "Micro"cosm: Magnifying the Nuance of Low Dose Buprenorphine Inductions.
J Opioid Manag
September 2024
Background: Now that the X-wavier is a thing of the past, patients with Opioid Use Disorder (OUD) who previously lacked access to buprenorphine may have access to lower barrier care and may be looking to make the transition from either methadone or illicit fentanyl to buprenorphine. This can be quite challenging and both fentanyl and methadone are hihghly potent drugs and can result in a difficult transtition to buprenorphine.
Purpose/hypothesis: A transition from high potency opioids to buprenorphine is challenging and can cause discomfort or withdrawal in patients.
Successful pain control with add-on methadone for refractory neuropathic pain due to radiation necrosis in pontine metastatic lesion: a case report.
BMC Palliat Care
August 2024
Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, 329-0498, Tochigi, Japan.
Background: Central pain, characterized by neuropathic pain, can manifest due to injury to the superior spinothalamic tract. The brainstem includes sensory and motor pathways as well as nuclei of the cranial nerves, and therefore cancer metastasis in the region requires early intervention. Although stereotactic radiosurgery (SRS) is commonly employed for the treatment of brain metastasis, it poses risks of late complications like radiation necrosis (RN).
View Article and Find Full Text PDFThe immunological and pharmacokinetic evaluation of Lipid-PLGA hybrid nanoparticle-based oxycodone vaccines.
Biomaterials
February 2025
Department of Biological Systems Engineering, College of Engineering & College of Agricultural and Life Sciences, Virginia Tech, Blacksburg, VA, 24061, USA. Electronic address:
Article Synopsis
- The opioid epidemic is a major public health crisis in the U.S., with limited treatment options for opioid use disorder (OUD) primarily focused on medications like methadone and naloxone.
- Emerging vaccine strategies, particularly a hybrid nanoparticle (hNP)-based vaccine against oxycodone, show promise for improving treatment outcomes by enhancing immune responses and preventing misuse.
- The hNP-based vaccine, using keyhole limpet hemocyanin and aluminum hydroxide, demonstrated superior effectiveness in mice, suggesting it could be a more potent alternative to conventional conjugate vaccines for combating OUD.
Novel drug treatments for pain in advanced cancer and serious illness: a focus on neuropathic pain and chemotherapy-induced peripheral neuropathy.
Palliat Care Soc Pract
July 2024
Geisinger Commonwealth School of Medicine, 100 North Academy Avenue, Danville, PA 17822, USA.
Article Synopsis
- Some medicines that are already available could help reduce pain in new ways, and this review talks about four of them: haloperidol, miragabalin, palmitoylethanolamide (PEA), and clonidine.
- Haloperidol might help with pain when combined with other pain medicines, but the evidence is not very strong; it’s mostly used for patients with cancer and certain pain types.
- Miragabalin and PEA have shown better results in trials for treating different kinds of nerve pain, while clonidine is used for various conditions including ADHD and cancer-related pain and works by calming down nerve activity to reduce pain feelings.
Methadone in combination with magnesium, ketamine, lidocaine, and dexmedetomidine improves postoperative outcomes after coronary artery bypass grafting: an observational multicentre study.
J Cardiothorac Surg
June 2024
Department of Cardiac Surgery, Epworth Eastern Hospital, Melbourne, Australia.
Background: An optimal pharmacological strategy for fast-track cardiac anesthesia (FTCA) is unclear. This study evaluated the effectiveness and safety of an FTCA program using methadone and non-opioid adjuvant infusions (magnesium, ketamine, lidocaine, and dexmedetomidine) in patients undergoing coronary artery bypass grafting.
Methods: This retrospective, multicenter observational study was conducted across private and public teaching sectors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!